These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36291690)

  • 1. Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study.
    Chen R; Zhao H; Zhou J; Wang Y; Li J; Zhao X; Li N; Liu C; Zhou P; Chen Y; Song L; Yan H
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of Proprotein Convertase Subtilisin/Kexin Type 9 to Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention.
    Choi IJ; Lim S; Lee D; Lee WJ; Lee KY; Kim MJ; Jeon DS
    Am J Cardiol; 2020 Oct; 133():54-60. PubMed ID: 32798044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI.
    Zhao X; Song L; Wang Y; Li J; Zhou J; Chen R; Liu C; Zhou P; Sheng Z; Chen Y; Zhao H; Yan H
    J Inflamm Res; 2021; 14():5319-5335. PubMed ID: 34703271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impacts of Lipoxin A4 in patients with acute myocardial infarction: A prospective cohort study.
    Chen R; Li J; Zhou J; Wang Y; Zhao X; Li N; Liu W; Liu C; Zhou P; Chen Y; Yan S; Song L; Yan H; Zhao H
    Pharmacol Res; 2023 Jan; 187():106618. PubMed ID: 36549409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
    O'Donoghue ML; Fazio S; Giugliano RP; Stroes ESG; Kanevsky E; Gouni-Berthold I; Im K; Lira Pineda A; Wasserman SM; Češka R; Ezhov MV; Jukema JW; Jensen HK; Tokgözoğlu SL; Mach F; Huber K; Sever PS; Keech AC; Pedersen TR; Sabatine MS
    Circulation; 2019 Mar; 139(12):1483-1492. PubMed ID: 30586750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute-Phase Plasma PCSK9 Levels and Recurrent Cardiovascular Events in a Chinese Acute Myocardial Infarction Cohort.
    Gao Y; Qiu Y; Wu J; Diao W; Zhang H; Wang S; Du Z; Dong J; Zhang M; Jiang L
    Cardiology; 2018; 141(2):88-97. PubMed ID: 30423567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction.
    Zhang Z; Wei TF; Zhao B; Yin Z; Shi QX; Liu PL; Liu LF; Liu L; Zhao JT; Mao S; Rao MM; Wang SL; Chen YD
    Sci Rep; 2019 Feb; 9(1):3113. PubMed ID: 30816133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study.
    Peng J; Liu MM; Jin JL; Cao YX; Guo YL; Wu NQ; Zhu CG; Dong Q; Sun J; Xu RX; Li JJ
    Cardiovasc Diabetol; 2020 Oct; 19(1):167. PubMed ID: 33023603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
    Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.
    Likozar AR; Šebeštjen M
    Cardiovasc Ultrasound; 2023 Aug; 21(1):15. PubMed ID: 37580777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes.
    Song L; Zhao X; Chen R; Li J; Zhou J; Liu C; Zhou P; Wang Y; Chen Y; Zhao H; Yan H
    Cardiovasc Diabetol; 2022 May; 21(1):80. PubMed ID: 35596184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
    El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
    Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
    Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
    Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.
    Zhang Y; Liu J; Li S; Xu RX; Sun J; Tang Y; Li JJ
    BMC Cardiovasc Disord; 2014 Dec; 14():192. PubMed ID: 25519174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
    Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
    Langsted A; Nordestgaard BG; Benn M; Tybjærg-Hansen A; Kamstrup PR
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3281-7. PubMed ID: 27218270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.
    Li JJ; Li S; Zhang Y; Xu RX; Guo YL; Zhu CG; Wu NQ; Qing P; Gao Y; Sun J; Liu G; Dong Q
    Medicine (Baltimore); 2015 Dec; 94(52):e2426. PubMed ID: 26717403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.